Target intelligence / Profile preview

Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) (IDH1)

Target
IDH1
Molecular classification
Enzyme, Oxidoreductase
01

Overview

Isocitrate dehydrogenase 1 (IDH1) is a critical metabolic enzyme located in the cytoplasm and peroxisomes that catalyzes the reversible oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), producing NADPH in the process (UniProt O75874). While the wild-type enzyme maintains cellular redox balance and supports lipid synthesis, specific somatic mutations—most frequently at the R132 residue—grant the enzyme a neomorphic gain-of-function (Nature, 2009, 462:739-744). This mutant form converts α-KG into the oncometabolite D-2-hydroxyglutarate (2-HG), which competitively inhibits α-KG-dependent dioxygenases, including histone demethylases and TET family DNA hydroxylases (PubMed, 23412291). The resulting epigenetic hypermethylation leads to impaired cellular differentiation and promotes the development of various malignancies such as acute myeloid leukemia, low-grade gliomas, and cholangiocarcinoma (FDA, Tibsovo Prescribing Information). Pharmacological targeting of mutant IDH1 with small-molecule inhibitors aims to lower 2-HG levels, thereby restoring normal epigenetic signaling and inducing the differentiation of malignant cells (StatPearls, NBK545234). These inhibitors are specifically designed to bind the mutant protein, though some dual inhibitors also target the related IDH2 isoform or show varying degrees of selectivity against the wild-type enzyme (Nature Reviews Cancer, 2017, 17:71-83). Clinical management of patients on these therapies requires monitoring for differentiation syndrome, a potentially fatal condition characterized by rapid proliferation and differentiation of myeloid cells (FDA, Rezlidhia Label).

Other names
Isocitrate dehydrogenase 1IDPIDPCPICDNADP(+)-specific isocitrate dehydrogenase, cytosolicOxalosuccinate decarboxylase
02

Mechanism of action

Small-molecule inhibition of the mutant IDH1 enzyme to suppress the production of the oncometabolite D-2-hydroxyglutarate (2-HG), thereby reversing epigenetic dysregulation and promoting cellular differentiation.

03

Biological functions

MetabolismTricarboxylic acid cycleRedox homeostasisNADPH productionLipid biosynthesis
04

Disease associations

CancerAcute myeloid leukemiaGliomaCholangiocarcinomaChondrosarcoma
05

Safety considerations

Differentiation syndromeQTc interval prolongationHepatotoxicityGuillain-Barre syndrome
06

Interacting drugs

Ivosidenib

2 more in the full profile.

07

Biomarkers

IDH1 R132 mutation statusD-2-hydroxyglutarate (2-HG) levels

Beyond the preview

Go deeper on Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) (IDH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) (IDH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call